[go: up one dir, main page]

BR9808515A - Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective estrogen receptor modulators - Google Patents

Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective estrogen receptor modulators

Info

Publication number
BR9808515A
BR9808515A BR9808515-8A BR9808515A BR9808515A BR 9808515 A BR9808515 A BR 9808515A BR 9808515 A BR9808515 A BR 9808515A BR 9808515 A BR9808515 A BR 9808515A
Authority
BR
Brazil
Prior art keywords
treatment
prophylaxis
prostate cancer
selective estrogen
receptor modulators
Prior art date
Application number
BR9808515-8A
Other languages
Portuguese (pt)
Inventor
Blake Lee Neubauer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9808515A publication Critical patent/BR9808515A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Patente de Invenção: <B>"TRATAMENTO OU PROFILAXIA DE CâNCER DE PRóSTATA E HIPERPLASIA BENIGNA DA PRóSTATA COM MODULADORES DE RECEPTORES DE ESTROGêNIO SELETIVOS"<D>. A presente invenção refere-se a um método de tratamento ou profilaxia de hiperplasia benigna da próstata ou câncer de próstata em um paciente com necessidade de tal tratamento, compreendendo a administração de um composto de fórmula (I) modulador de receptores de estrogênio seletivos, onde R¹ e R² são independentemente hidróxi ou alcóxi de um a quatro átomos de carbono; e R³ e R^ 4^ são independentemente metila ou etila, ou R³ e R^ 4^, tomados junto com o átomo de nitrogênio ao qual estão ligados, formam um anel pirrolidino, metilpirrolidino, dimetilpirrolidino, piperidino, morfolino ou hexametilenoimino.Invention Patent: <B> "TREATMENT OR PROPHYLAXIS OF PROSTATE CANCER AND BENIGN PROSTATE HYPERPLASIA WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS" <D>. The present invention relates to a method of treatment or prophylaxis of benign prostatic hyperplasia or prostate cancer in a patient in need of such treatment, comprising administering a compound of formula (I) modulating selective estrogen receptors, where R¹ and R² are independently hydroxy or alkoxy of one to four carbon atoms; and R³ and R ^ 4 ^ are independently methyl or ethyl, or R³ and R ^ 4 ^, taken together with the nitrogen atom to which they are attached, form a pyrrolidine, methylpyrrolidine, dimethylpyrrolidine, piperidine, morpholino or hexamethyleneimino ring.

BR9808515-8A 1997-04-09 1998-04-07 Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective estrogen receptor modulators BR9808515A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4322397P 1997-04-09 1997-04-09
PCT/US1998/007274 WO1998045288A1 (en) 1997-04-09 1998-04-07 Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
BR9808515A true BR9808515A (en) 2001-06-19

Family

ID=21926126

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808515-8A BR9808515A (en) 1997-04-09 1998-04-07 Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective estrogen receptor modulators

Country Status (16)

Country Link
EP (1) EP0975629A4 (en)
JP (1) JP2001518900A (en)
KR (1) KR20010006218A (en)
CN (1) CN1259944A (en)
AU (1) AU6966198A (en)
BR (1) BR9808515A (en)
CA (1) CA2286204A1 (en)
EA (1) EA199900914A1 (en)
HU (1) HUP0003589A3 (en)
ID (1) ID24358A (en)
IL (1) IL132277A0 (en)
NO (1) NO994903L (en)
PL (1) PL336205A1 (en)
TR (1) TR199902701T2 (en)
WO (1) WO1998045288A1 (en)
ZA (1) ZA982819B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
EP1392304A1 (en) * 2001-05-10 2004-03-03 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostate cancer
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
US7825107B2 (en) * 2006-05-22 2010-11-02 Hormos Medical Ltd. Method of treating men suffering from chronic nonbacterial prostatitis with SERM compounds or aromatase inhibitors
EA022760B1 (en) 2007-10-16 2016-02-29 Репрос Терапьютикс Инк. Use of trans-clomiphene for prevention or treatment of type 2 diabetes in men
AU2013225869B2 (en) 2012-02-29 2017-06-08 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
MA38325B1 (en) 2013-02-19 2019-03-29 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degradation agents
JP7048505B2 (en) 2015-11-10 2022-04-05 パラクリン セラピューティクス エービー Treatment of ER-negative breast cancer with PDGF-CC inhibitors and antiestrogens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429922A (en) * 1988-03-09 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for distinguishing virulent and non-virulent toxoplasma infections
JP3989569B2 (en) * 1995-02-28 2007-10-10 イーライ リリー アンド カンパニー Benzothiophene compounds, intermediates, compositions and methods
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
PL336205A1 (en) 2000-06-05
AU6966198A (en) 1998-10-30
ID24358A (en) 2000-07-13
HUP0003589A3 (en) 2002-02-28
EP0975629A4 (en) 2001-03-21
NO994903L (en) 1999-12-09
JP2001518900A (en) 2001-10-16
CA2286204A1 (en) 1998-10-15
WO1998045288A1 (en) 1998-10-15
NO994903D0 (en) 1999-10-08
EP0975629A1 (en) 2000-02-02
ZA982819B (en) 1999-10-04
IL132277A0 (en) 2001-03-19
KR20010006218A (en) 2001-01-26
EA199900914A1 (en) 2000-04-24
HUP0003589A2 (en) 2002-01-28
TR199902701T2 (en) 2000-02-21
CN1259944A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
BR9809389A (en) Treatment of central nervous system disorders with selective estrogen receptor modulations
EA200000220A1 (en) COMBINATION OF TYROSINKINASE INHIBITOR AND CHEMICAL STERILIZATION FOR TREATMENT OF PROSTATE GLAND
AU674477B2 (en) Heterocyclic-cyclic amine derivatives
GB9514473D0 (en) Chemical compounds
KR100263496B1 (en) Taxol derivatives and preparation method thereof
EP1009755A4 (en) Steroid sulfatase inhibitors and methods for making and using the same
BR9808515A (en) Treatment or prophylaxis of prostate cancer and benign prostatic hyperplasia with selective estrogen receptor modulators
YU48698A (en) Carboxamide derivatives of pyrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorder
KR20000005379A (en) Isatin derivatives as acetylcholinesterase inhibitors and analgesics
GB9727521D0 (en) Substituted 2-benzylamino-2-phenyl-acetamide compounds
PL341050A1 (en) Heterocyclic cytoxic agents
LU92263I2 (en) Imépitoin and its pharmaceutically acceptable derivatives (PEXION)
TR200001288T2 (en) 2-arylbenzo (b) thiophene useful in the treatment of estrogen withdrawal syndrome.
PT1189923E (en) AROMATIC AND HETEROCYCLIC DERIVATIVES OF PHYTOSTEROIS AND / OR FITOSTANES FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASE
AUPR118000A0 (en) Therapeutic molecules and methods
AU2393997A (en) Alpha1-adrenergic receptor antagonists
EA199900910A1 (en) BREAST CANCER PREVENTION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS
YU46302A (en) Substituted pyrroles
MX9701327A (en) Methods of inhibiting endometrial cancer.
NO994107L (en) Preparations for the treatment or prevention of prostate cancer
EP0551952A3 (en) 17-aryl-substituted steroidal compounds active on the cardiovascular system
MX9706520A (en) Methods of inhibiting ovarian cancer.
MX9806036A (en) Methods of inhibiting colon tumors.
GR3036968T3 (en) Adamantyl substituted oxindoles as pharmaceutical agents
MX9603797A (en) Therapeutic agents for use in cancer therapy.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]